.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Cipla
Julphar
Argus Health
Farmers Insurance
Cantor Fitzgerald
Dow
Express Scripts
Moodys
AstraZeneca

Generated: July 22, 2017

DrugPatentWatch Database Preview

Meda Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for MEDA PHARMS, and what generic alternatives to MEDA PHARMS drugs are available?

MEDA PHARMS has six approved drugs.

There are two US patents protecting MEDA PHARMS drugs.

There are thirteen patent family members on MEDA PHARMS drugs in nine countries.

Summary for Applicant: Meda Pharms

Patents:2
Tradenames:6
Ingredients:6
NDAs:6
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Meda Pharms
REGLAN ODT
metoclopramide hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021793-002Jun 10, 2005DISCNNoNo6,024,981► SubscribeY ► Subscribe
Meda Pharms
SOMA COMPOUND
aspirin; carisoprodol
TABLET;ORAL012365-005Jul 11, 1983DISCNNoNo► Subscribe► Subscribe
Meda Pharms
ROWASA
mesalamine
SUPPOSITORY;RECTAL019919-001Dec 18, 1990DISCNYesNo► Subscribe► Subscribe
Meda Pharms
SOMA COMPOUND W/ CODEINE
aspirin; carisoprodol; codeine phosphate
TABLET;ORAL012366-002Jul 11, 1983DISCNNoNo► Subscribe► Subscribe
Meda Pharms
REGLAN ODT
metoclopramide hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021793-001Jun 10, 2005DISCNNoNo6,221,392► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Meda Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Meda Pharms
SOMA COMPOUND
aspirin; carisoprodol
TABLET;ORAL012365-005Jul 11, 19834,534,973► Subscribe
Meda Pharms
SOMA COMPOUND W/ CODEINE
aspirin; carisoprodol; codeine phosphate
TABLET;ORAL012366-002Jul 11, 19834,534,974► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Meda Pharms Drugs

Country Document Number Estimated Expiration
Japan2008001726► Subscribe
World Intellectual Property Organization (WIPO)9846215► Subscribe
Denmark2147669► Subscribe
Japan2012162558► Subscribe
European Patent Office0975336► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Meda Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
12/008Ireland► SubscribePRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
C0026France► SubscribePRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
C/GB98/031United Kingdom► SubscribePRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
C/GB08/020United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/020 GRANTED TO ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. IN RESPECT OF THE PRODUCT RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6346 DATED 05 JANUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 JANUARY 2023.
C0025Belgium► SubscribePRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Teva
AstraZeneca
US Department of Justice
McKinsey
Baxter
Chinese Patent Office
Merck
Harvard Business School
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot